skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

The cell line OE33, also known as JROECL33, was established from the adenocarcinoma of the lower oesophagus (Barrett's metaplasia) of a 73 year old female patient. The tumour was identified as pathological stage IIA (UICC) and showed poor differentiation. OE33 express HLA-A, -B and -C antigens (MHC class I) and ICAM-1 constitutively. Expression of HLA-DR (MHC class II) can be induced by treatment with interferon-gamma. The cells express epithelial cytokeratins and are tumourigenic in nude mice.Cultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer



MHC class I, ICAM-1

Tissue of Origin


DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D5S818: 11
D7S820: 9,10
D13S317: 14
D16S539: 12
TH01: 7,8
TPOX: 8,11
vWA: 17




Study of oesophageal cancer



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures (70-80%) 1:8 i.e. seeding at 1x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Initially these cells grow slowly and can take up to 7 days until ready for the next split, 50% media changes will be necessary every 2-3 days (i.e. replacing half the old medium with fresh).

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Growth Mode


Additional Info


Drs J C Rockett/A Morriss, Department of Biological Sciences, University of Warwick and Dr S J Darnton, Birmingham Heartlands Hospital

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2



Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR 1997 Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer. 75(2):258-63 PMID: 9010035Whole-genome sequencing of nine esophageal adenocarcinoma cell lines


Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. 2010 Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 102(4):271-4.PMID: 20075370. Barretina J, et al., 2012 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483(7391):603-7. PMID: 22460905.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: OE33 (ECACC 96070808).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.